Definition of First-Line Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer Reply

被引：0
作者：
Ellis, Matthew J. [1 ]
Robertson, John F. R. [2 ]
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Univ Nottingham, Derby, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 16期
关键词：
FULVESTRANT; 500; MG; ANASTROZOLE; TRIAL; 1ST;
D O I：
10.1200/JCO.2016.66.6727
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1960 / +
页数：3
相关论文
共 50 条
  • [41] Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients
    Shimizu, Daisuke
    Ishikawa, Takashi
    Tanabe, Mikiko
    Sasaki, Takeshi
    Ichikawa, Yasushi
    Chishima, Takashi
    Endo, Itaru
    BREAST CANCER, 2014, 21 (05) : 557 - 562
  • [42] Efficacy and acceptability of neoadjuvant endocrine therapy in patients with hormone receptor-positive breast cancer: A network meta-analysis
    Zhang, Tingting
    Feng, Fubin
    Yao, Yan
    Qi, Lingyu
    Tian, Jinhui
    Zhou, Chao
    Dong, Shengjie
    Wang, Xue
    Sun, Changgang
    JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (08) : 12393 - 12403
  • [43] The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer
    Zhang, Ailin
    Wang, Xiaojing
    Fan, Chuifeng
    Mao, Xiaoyun
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [44] A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer
    Yadav, Siddhartha
    Giridhar, Karthik, V
    Leone, Jose Pablo
    Leon-Ferre, Roberto A.
    Ruddy, Kathryn J.
    BREAST CANCER MANAGEMENT, 2021, 10 (03)
  • [45] Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer A network meta-analysis
    Zhang, Jingwen
    Huang, Yanhong
    Wang, Changyi
    He, Yuanfang
    Zheng, Shukai
    Wu, Kusheng
    MEDICINE, 2017, 96 (33)
  • [46] Palbociclib: A Novel Cyclin-Dependent Kinase Inhibitor for Hormone Receptor-Positive Advanced Breast Cancer
    Mangini, Neha S.
    Wesolowski, Robert
    Ramaswamy, Bhuvaneswari
    Lustberg, Maryam B.
    Berger, Michael J.
    ANNALS OF PHARMACOTHERAPY, 2015, 49 (11) : 1252 - 1260
  • [47] Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study
    Gonzalez, Ana Lopez
    Del Barco Berron, Sonia
    Grau, Isabel
    Galan, Maria
    Castelo Fernandez, Beatriz
    Cortes, Alfonso
    Sanchez Rovira, Pedro
    Martinez-Bueno, Alejandro
    Gonzalez, Xavier
    Garcia, Almudena
    Gener, Petra
    Mina, Leonardo
    Alcala-Lopez, Daniel
    Sampayo, Miguel
    Cortes, Javier
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Lopez-Miranda, Elena
    CANCERS, 2022, 14 (23)
  • [48] Extending the Clinical Benefit of Endocrine Therapy for Women With Hormone Receptor-Positive Metastatic Breast Cancer: Differentiating Mechanisms of Action
    Glueck, Stefan
    CLINICAL BREAST CANCER, 2014, 14 (02) : 75 - 84
  • [49] Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept
    Iwata, Hiroji
    BREAST CANCER, 2011, 18 (02) : 92 - 97
  • [50] Endocrine Therapy in the Current Management of Postmenopausal Estrogen Receptor-Positive Metastatic Breast Cancer
    Kaklamani, Virginia G.
    Gradishar, William J.
    ONCOLOGIST, 2017, 22 (05) : 507 - 517
12345